A wave of patent expirations beginning later this month is set to open the door to generic versions of semaglutide in major markets.
The World Health Organization designated semaglutide an essential medicine last year. Experts say that if generic production reduces prices to sustainable levels, large-scale treatment could extend into low- and middle-income countries, much as has occurred with therapies for HIV, tuberculosis, and malaria. They caution that medication availability alone will not address root causes such as poverty and food insecurity.
Regulatory timelines are central to how quickly cheaper versions might spread. Semaglutide will lose patent protection in countries including Brazil, China, India, Turkey, Mexico, and Canada later this month as core patents expire in phases. Data protection already expired in Canada in January, enabling generic versions. Patents remain valid for about the next five years in the UK, continental Europe, and the United States, and in South Korea until June 2028. Approximately 150 countries—most in Africa—never had patents filed for semaglutide at all, a gap that could allow broader generic availability in roughly 160 countries where type 2 diabetes and obesity are highly prevalent, according to Bloomberg.
Competition in Canada
In Canada, competition is already taking shape. Vimy Pharma, a newly formed domestic company, says it plans to file its application for generic semaglutide with Health Canada in the coming weeks. Eight other applications for generic semaglutide are already under review by the regulator. “You could say we’re betting everything on this one drug,” co-founder David Suchon said, according to CBC News. If approved, Vimy’s version would be mass-produced at a new critical medicines production centre in Edmonton run by Applied Pharmaceutical Innovation. Ozempic is approved in Canada for diabetes and to slow kidney decline and is also widely used for weight loss, underscoring the strong demand any generic entrant would confront. Co-founder Farris Smith believes there is growing support among Canadians for local brands and companies, positioning the startup to appeal to patients and payers seeking lower costs.
A massive market
The scale of the potential market is substantial. Obesity and diabetes are chronic diseases that raise the risk of stroke, heart disease, kidney failure, and cancer. More than one billion people worldwide now live with obesity, with rates rising rapidly in lower-income nations. Clinical obesity contributes to 3.7 million deaths annually. Semaglutide’s record in both diabetes management and weight reduction has elevated it to blockbuster status, and its designation as an essential medicine has further highlighted the urgency of bringing prices down as barriers fall in much of the world.
Near-term access will vary widely by geography. In markets where patents remain in force—particularly the US and Europe—patients are likely to continue facing high list prices, even if some discounts and direct-to-consumer offerings help reduce out-of-pocket costs for certain doses. In countries where protections lapse this month or were never filed, generics could proliferate far sooner. Analysts point to manufacturing advances that may drive costs down for both injectable and oral forms. Advocates for broader access argue that replicating the global playbook used for other essential medicines—combining patent landscapes favorable to competition, efficient generic production, and public procurement—could bring semaglutide within reach of millions more people. They note that medications are only one part of a wider response to metabolic disease, with sustained investment in nutrition, prevention, and socioeconomic supports necessary to confront the drivers of obesity and diabetes at their roots.